Test Price
2,800 AED✅ Home Collection Available
NRAS Gene Mutation Analysis for Hereditary Colorectal Cancer – Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary — UAE Clinical Excellence
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — serving all Emirates, daily 8 AM – 11 PM.
- ✓Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed specialists.
- ✓Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 — confirm coverage before your draw.
Test Overview & Methodology
The NRAS Gene Mutation Analysis is a comprehensive genetic test designed to detect pathogenic variants in the NRAS oncogene associated with hereditary colorectal cancer syndromes. This advanced molecular diagnostic evaluates the full coding region of NRAS using Next-Generation Sequencing (NGS), enabling precise risk stratification for patients with a family history of colorectal malignancies.
| Parameter | Our Test — NGS NRAS Full Gene | Closest Alternative — Hotspot Panel |
|---|---|---|
| Methodology | Next Generation Sequencing (NGS) — Full Gene Coverage | Targeted Hotspot Genotyping / Sanger Sequencing |
| Diagnostic Sensitivity | 99.9% — ISO 9001:2015 Validated | ~92–95% — Limited to Known Hotspot Loci |
| Turnaround Time | 3 to 4 Weeks — Comprehensive Bioinformatics Pipeline | 1 to 2 Weeks — Limited Analysis |
| Facility Accreditation | ISO 9001:2015 | DHA License 1143 | Variable — May Lack UAE-Specific Accreditation |
| Clinical Utility | Hereditary CRC Risk Assessment, Family Screening, Targeted Therapy Guidance | Limited to Common Mutations; May Miss Rare Pathogenic Variants |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) — "Genetic testing for NRAS mutations provides crucial information for hereditary cancer risk assessment, but results must always be interpreted within the full context of personal and family medical history. A positive result indicates increased risk, not a diagnosis; a negative result does not eliminate baseline population risk. Pre- and post-test genetic counselling is essential to understand implications for the patient and at-risk relatives, including cascade testing options."
Critical Medication Advisory
⚠ Important Notice
Do not stop or modify any prescribed treatment — including chemotherapy, targeted therapy, or prophylactic regimens — without consulting your treating oncologist. Genetic test results provide risk stratification and therapeutic guidance; they are not a sole basis for altering an established treatment plan. Clinical correlation with imaging, histopathology, and laboratory biomarkers remains essential.
Patient Safety — Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed Without Clinical Clearance):
- Allogeneic blood transfusion within the preceding 14 days (may confound germline DNA analysis).
- Active hematologic malignancy with circulating blasts >5% in peripheral blood.
- Inability to provide informed consent — including minors without guardian authorization per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Unstable psychiatric condition precluding meaningful genetic counselling engagement.
Emergency Red Flags — Seek Immediate Medical Attention:
- Acute onset of severe anxiety, panic, or suicidal ideation triggered by genetic risk disclosure.
- Unexpected incidental findings suggestive of an acute oncologic emergency (e.g., new-onset rectal bleeding, unexplained weight loss >10% in 3 months).
- Receipt of results indicating a pathogenic variant with urgent clinical actionability — contact our on-call genetic counsellor immediately via +971 54 548 8731.
Patient FAQ & Clinical Guidance
1. What is the NRAS gene test and why is it important for hereditary colorectal cancer screening?
The NRAS gene test uses Next-Generation Sequencing to analyze the full coding region of the NRAS oncogene for mutations linked to hereditary colorectal cancer syndromes. It is important because it identifies pathogenic variants that significantly increase lifetime cancer risk, enabling early surveillance, preventive measures, and targeted therapy options for affected individuals and their at-risk first-degree relatives.
2. How is the NRAS genetic test performed and what is the turnaround time?
A peripheral blood sample is collected via routine venipuncture at our facility or through our mobile phlebotomy service. Alternatively, extracted DNA or a single drop of blood on an FTA card can be used. The sample is processed using NGS with full gene coverage. Turnaround time is 3 to 4 weeks due to comprehensive bioinformatics analysis. Pre-test genetic counselling and a pedigree chart session are mandatory components prior to sample collection.
3. Is this NRAS genetic test covered by health insurance in the UAE?
Insurance coverage varies by provider and plan; our team offers complimentary direct billing verification before your appointment. Many UAE insurers now recognize hereditary cancer genetic testing as a medically necessary diagnostic service when supported by a referral from a DHA-licensed oncologist or gastroenterologist. We facilitate pre-authorization requests and verify coverage across major networks including Daman, AXA, Oman Insurance, and Neuron. For uninsured or self-pay patients, the test is priced at 2800 AED inclusive of genetic counselling, phlebotomy, and post-test guidance. Contact our billing team via WhatsApp at +971 54 548 8731 to verify your coverage in under 15 minutes.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Accreditation
📚 Federal Decree-Law No. 45 of 2021 (PDPL)
All genetic data collected, stored, and processed in full compliance with UAE Personal Data Protection Law. Patient genomic information is classified as sensitive personal data and handled per statutory encryption and retention protocols.
👮 Federal Law No. 2 of 2019 (ICT Health)
Use of information and communication technology in health fields, ensuring secure electronic health records and telemedicine practices for genetic counselling and result delivery.
🔒 Federal Decree-Law No. 4 of 2016 (Medical Liability)
Informed consent and patient safety protocols for genetic testing adhere to medical liability standards, including guardian authorization for minors and mandatory pre-test counselling.
Clinical & Logistical Metadata
| Test Name | NRAS Gene Mutation Analysis (Full Gene Sequencing) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA tube) or Extracted DNA |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | Z80.3 |
| LOINC Code | 93027-1 |
| DHA Facility License & Address | DHA Facility License No: 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians